← Leaderboards
Kent W Kirshenbaum
California Institute Of Technology
$1,235,546
Attributed
$2,205,063
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $624K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,205,063 · 5
By mechanism
R01$1,199,699 · 1
R21$397,284 · 1
P41$273,366 · 1
R41$256,538 · 1
F32$78,176 · 1
Top collaborators
- Michael J Garabedian4 shared
- Annelise Emily Barron1 shared
- Peter Luke Santa Maria1 shared
Most similar at California Institute Of Technology
Same institution · by research overlap
- Dennis A Dougherty$8,653,143
- David A Tirrell$6,473,942
- Stephen M Contakes$108,081
- Jin Kim Montclare$1,504,119
- Paul W.k. Rothemund$460,625
Others in their field
Top investigators on “Peptoids”
- Thomas J. Kodadek · University Of Florida$12,678,068
- Garry P Nolan · Stanford University$10,187,880
- Peter Sarnow · Stanford University$4,810,759
- Annelise Emily Barron · Northwestern University$4,383,488
- Victoria Auerbuch Stone · University Of California Santa Cruz$3,002,223
- Thomas M Wisniewski · Nathan S. Kline Institute For Psych Res$2,919,270
Research focus
PeptoidsAffectInnovationFamilyPeptide HydrolasesCellsIn VivoIn Vivo EvaluationGrowthPathway InteractionsPharmacologyAndrogen ReceptorMalignant Neoplasm Of ProstateGenetic TranscriptionLigand BindingMutationAndrogen AntagonistsInvestigationAffinityBindingLigandsAntitumor ResponseNovel TherapeuticsProstate Cancer Cell
Grant awards (10)
Peptoid conjugates targeting prostate cancer$575,698
R01 · FY2025 · CA
Peptoid conjugates targeting prostate cancer$624,001
R01 · FY2024 · CA
Synthetic Antimicrobial Peptoids for Treatment of Chronic Suppurative Otitis Media$256,538
R41 · FY2021 · DC · contact PI
Peptoid conjugates as inhibitors of androgen receptor dimerization and function in enzalutamide-resistant prostate cancer$180,449
R21 · FY2020 · CA
Peptoid conjugates as inhibitors of androgen receptor dimerization and function in enzalutamide-resistant prostate cancer$216,835
R21 · FY2019 · CA
CONFORMATIONALLY CONSTRAINED PROTEIN POLYMERS$12,428
F32 · FY2002 · GM
PREDICTING CONFORMATIONAL SWITCHES IN PROTEINS$273,230
P41 · FY2001 · RR
CONFORMATIONALLY CONSTRAINED PROTEIN POLYMERS$34,832
F32 · FY2001 · GM
CONFORMATIONALLY CONSTRAINED PROTEIN POLYMERS$30,916
F32 · FY2000 · GM
PREDICTING CONFORMATIONAL SWITCHES IN PROTEINS$136
P41 · FY2000 · RR